Sacituzumab Govitecan-hziy Approved for HR-Positive Breast Cancer

The FDA has granted approval to sacituzumab govitecan-hziy (Trodelvy®, Gilead Sciences, Inc.) for treatment of unresectable, locally advanced, or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. Patients are required to have received at least one prior line of endocrine therapy and two systemic therapies in the metastatic setting. "Sacituzumab govitecan is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)–directed antib...

Continue reading

Elacestrant Approved for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer

The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression subsequent to at least one line of endocrine therapy. Additionally, the FDA approved the Guardant360 CDx assay, a companion diagnostic test, to identify breast cancer patients eligible for treatme...

Continue reading

Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD

In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them. 

Continue reading

Uncovering Racial Disparities Experienced in Breast Cancer Patients With Yara Abdou, MD

At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to go into further detail on her findings, as well as to answer a few questions regarding future clinical trials and research to explore disparities Blac...

Continue reading

Addressing Knowledge Gaps in Metastatic Triple-Negative Breast Cancer Treatment and Care

An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United States. Approximately 15% of cases are classified as triple-negative, lacking expression of estrogen, progesterone, and human epidermal growth factor 2 (H...

Continue reading

Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD

In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).  

Continue reading

Breast Cancer Is Not Just One Disease: Exploring Lobular Breast Cancer Research With Jason Mouabbi, MD

Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.   

Continue reading

An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH

In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  

Continue reading

A Faculty Preview of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies

Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of the educational topics they'll be covering at ODACon on November 12, as well as highlighting their individual research interests and their work in the...

Continue reading

Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS

In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 

Continue reading

Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS

In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 

Continue reading

Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS

In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.  

Continue reading

Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS

In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.  

Continue reading

The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 1

In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  

Continue reading

The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2

In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend. 

Continue reading

The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker

Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for ...

Continue reading

Oncology Data Advisor™ Announces New Data Hubs!

To continue our mission to deliver up-to-date, clinically relevant content from the health care community, we have created NEW Oncology Data Advisor Data Hubs. Each Data Hub is categorized by tumor type to make it easy for all members of the oncology team to find the most up-to-date information from across the health care landscape. View the Data Hubs below now! 

Exploring Treatment Outcomes for Lobular Breast Cancer With Jason Mouabbi, MD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jason Mouabbi of MD Anderson Cancer Center presented a poster focused on survival outcomes of patients with invasive lobular carcinoma treated with endocrine therapy plus a CDK4/6 inhibitor, mammalian target of rapamycin (mTOR) inhibitor, or a PI3K inhibitor, in comparison to those with metastatic hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive ductal carcinoma. Afterwards, he sat down with Oncology Data Advisor to explain the implication of the study's results and the need for additional research in the field of lobular breast cancer to improve patient outcomes. 

This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.  

Continue reading

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

Continue reading

Applying Recent Advances to Personalized Breast Cancer Care, A Breast Surgical Oncologist’s View: Brigid Killelea, MD, FACS

Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.  

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.